Segall Bryant & Hamill, LLC Galapagos Nv Call Options Transaction History
Segall Bryant & Hamill, LLC
- $7.16 Billion
- Q3 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding GLPG
# of Institutions
85Shares Held
12.3MCall Options Held
69.1KPut Options Held
42.7K-
Bvf Inc San Francisco, CA1.57MShares$42.6 Million1.44% of portfolio
-
Deerfield Management Company, L.P. (Series C) New York, NY1.41MShares$38.3 Million0.76% of portfolio
-
Prosight Management, LP Dallas, TX1.03MShares$27.9 Million7.95% of portfolio
-
Logos Global Management LP San Francisco, CA800KShares$21.7 Million3.05% of portfolio
-
Primecap Management CO Pasadena, CA720KShares$19.5 Million0.02% of portfolio
About GALAPAGOS NV
- Ticker GLPG
- Exchange OTC
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 65,835,500
- Market Cap $1.79B
- Description
- Galapagos NV, an integrated biopharmaceutical company, engages in the discovery, development, and commercialization of various medicines for high unmet medical need. Its pipeline products include filgotinib, a JAK1 inhibitor that is in various phases of clinical trials for the treatment of rheumatoid arthritis, Crohn's disease, ulcerative coliti...